PubMed Journals Articles About "Levodopa Carbidopa Intestinal Infusion Weight Loss Parkinson Disease" RSS

00:01 EDT 26th March 2019 | BioPortfolio

Levodopa Carbidopa Intestinal Infusion Weight Loss Parkinson Disease PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Levodopa Carbidopa Intestinal Infusion Weight Loss Parkinson Disease articles that have been published worldwide.

More Information about "Levodopa Carbidopa Intestinal Infusion Weight Loss Parkinson Disease" on BioPortfolio

We have published hundreds of Levodopa Carbidopa Intestinal Infusion Weight Loss Parkinson Disease news stories on BioPortfolio along with dozens of Levodopa Carbidopa Intestinal Infusion Weight Loss Parkinson Disease Clinical Trials and PubMed Articles about Levodopa Carbidopa Intestinal Infusion Weight Loss Parkinson Disease for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Levodopa Carbidopa Intestinal Infusion Weight Loss Parkinson Disease Companies in our database. You can also find out about relevant Levodopa Carbidopa Intestinal Infusion Weight Loss Parkinson Disease Drugs and Medications on this site too.

Showing "Levodopa carbidopa intestinal infusion weight loss Parkinson disease" PubMed Articles 1–25 of 33,000+

Levodopa-carbidopa intestinal gel infusion and weight loss in Parkinson's disease.

Weight loss (WL) is a frequent yet under-recognized complication of levodopa/carbidopa intestinal gel (LCIG) infusion, as well as a milestone of Parkinson disease (PD) disability progression. The complex association between weight loss, poor nutritional status, motor complications, and PD progression, however, remains unclear.

Levodopa-carbidopa intestinal gel treatment introduced by surgical gastrostomy in a patient of Parkinson's disease after Billroth II gastrojejunostomy.

A 68-year-old man, who had received Billroth II gastrojejunostomy because of duodenal ulcer at the age of 20, was diagnosed to have Parkinson's disease at age 57 years. The drug therapy has been effective in the first 10 years, however, recently he was suffering from troublesome dyskinesia and wearing-off in spite of diligent drug adjustments. Although the indication of levodopa-carbidopa intestinal gel (LCIG) treatment was good, percutaneous endoscopic gastrostomy was difficult because of abdominal adhesio...

Sensor-based algorithmic dosing suggestions for oral administration of levodopa/carbidopa microtablets for Parkinson's disease: a first experience.

Dosing schedules for oral levodopa in advanced stages of Parkinson's disease (PD) require careful tailoring to fit the needs of each patient. This study proposes a dosing algorithm for oral administration of levodopa and evaluates its integration into a sensor-based dosing system (SBDS).

A Man Made Manic: Levodopa-Carbidopa-Induced Mania in Traumatic Brain Injury.

Traumatic brain injury (TBI) has had increased notoriety in light of chronic traumatic encephalopathy in professional sports. However, despite the increased rate at which mood disorders affect this population, there remains little information on management of these disorders. TBI has also been implicated in the development of Parkinson disease, increasing the likelihood that patients may be treated with dopaminergic agents. Management of coexisting pathologies can become challenging, especially when confoun...

Mucuna Pruriens Combined with Carbidopa in Parkinson's Disease: A Case Report.

We present a 48-year-old woman with Parkinson's disease in whom carbidopa was added to Mucuna pruriens, resulting in marked motor improvement (documented on video and using MDS-UPDRS motor scores). This case report shows that adding a dopa-decarboxylase inhibitor (DDCI) to Mucuna pruriens coud fit well in a personalized approach for patients who are reluctant to start levodopa. Meanwhile, larger trials with a longer follow-up are needed to establish the true effects and tolerability of Mucuna pruriens plus ...

Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease.

Levodopa is the main treatment for symptoms of Parkinson's disease. Determining whether levodopa also has a disease-modifying effect could provide guidance as to when in the course of the disease the treatment with this drug should be initiated.


Thrombolysis and late thrombectomy can be performed in case of compatible radiological imaging. Anti-CGRP monoclonal antibodies seem more effective for the treatment of migraine. Siponimod can reduce significantly disability progression in secondarily progressive MS. Brand-to-generic levetiracetam switching does not cause recrudescence of epileptic seizures. A new definition of Alzheimer's disease using biomarkers of cerebrospinal fluid (CSF) and imaging provides a better understanding of the underlying mec...

Rationale and patient selection for interventional therapies in Parkinson's disease.

Parkinson's disease (PD) is increasing in prevalence due to a growing elderly population. Although there is no cure, there are exercise therapies and medications for mild to moderate disease. For more advanced disease, infusion or surgical interventions including deep brain stimulation surgery, levodopa carbidopa intestinal gel and subcutaneous apomorphine infusion are considered. As these interventions become increasingly available, it is imperative for a neurologist involved in the care of advanced PD to ...

Vitamin B6 deficiency caused by the use of levodopa.

There are indications that the use of levodopa/carbidopa can cause symptomatic vitamin B6 deficiency. However, this has only been described for patients who used the product in the form of an intestinal gel.

Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson's disease.

Human gut microbiota senses its environment and responds by releasing metabolites, some of which are key regulators of human health and disease. In this study, we characterize gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases. Bacterial tyrosine decarboxylases efficiently convert levodopa to dopamine, even in the presence of tyrosine, a competitive substrate, or inhibitors of human decarboxylase. In situ levels of levodopa are compromised by high abun...

The effect of continuous levodopa treatment during the afternoon hours.

The aim of this retrospective study was to investigate if patients with PD, who are treated with levodopa-carbidopa intestinal gel (LCIG), clinically worsen during the afternoon hours and if so, to evaluate whether this occurs in all LCIG-treated patients or in a sub-group of patients.

Duodenale levodopa and apomorphine infusion for motor complications in advanced Parkinson's disease.

Development of motor fluctuations and dyskinesia characterizes the transition from the early to the advanced Parkinson stage. Current oral therapeutic strategies aim at increasing the number of levodopa administrations and extending its benefit by the association of enzyme blockers (MAO- and COMT-inhibitors) and dopamine agonists. However, as disease progresses, mobility becomes progressively dependent on levodopa absorption and plasma bioavailability, resulting in disabling motor complications. If patients...

The association between Parkinson's disease symptom side-of-onset and performance on the MDS-UPDRS scale part IV: Motor complications.

Parkinson's disease (PD) is a neurodegenerative condition associated with aging characterized by loss of dopamine-producing neurons in the substantia nigra pars compacta and a reduction in dopamine levels in the striatum. PD is commonly treated using dopamine-replacement medication called levodopa. Levodopa has decreasing efficacy over time. Periods when levodopa is not effective at controlling symptoms of PD are called "OFF-time" or "medication-related motor fluctuations," (MRMF). One characteristic of PD ...

Effect of levodopa on handwriting tasks of different complexity in Parkinson's disease: a kinematic study.

Levodopa treatment does improve Parkinson's disease (PD) dysgraphia, but previous research is not in agreement about which aspects are most responsive. This study investigated the effect of levodopa on the kinematics of writing. Twenty-four patients with PD of less than 10 years duration and 25 age-matched controls were recruited. A practically defined off state method was used to assess the levodopa motor response, measured on the Unified Parkinson's Disease Rating Scale Part III. The kinematic features ...

Differential Expression of Striatal ΔFosB mRNA and FosB mRNA After Different Levodopa Treatment Regimens in a Rat Model of Parkinson's Disease.

Levodopa-induced dyskinesia (LID) is the main side effect associated with levodopa treatment and represents the biggest challenge for Parkinson's disease therapy. While the overexpression of ΔFosB transcription factor is related to the development of LID, few studies have been undertaken on fosB gene transcriptional regulation induced by levodopa in vivo. The aim of this study is to evaluate the expression of ΔFosB mRNA and FosB mRNA in the striatum after acute, chronic, and subchronic levodopa treatment ...

Masticatory function and oral sensorimotor ability in Parkinson's disease: Levodopa on versus off periods.

To evaluate masticatory function and oral sensorimotor ability (OSA) in elders with Parkinson's disease (PD) during the levodopa on and off-periods.

A Transitional Probability Model for Parkinson's Disease Motor States With Applications to Missing Data.

Parkinson's disease (PD) is a progressive neurodegenerative disorder with significant disability. Subjects with advanced PD often suffer from motor complications that may interfere significantly with their daily activities. Levodopa (LD) in combination with a dopa decarboxylase inhibitor such as carbidopa (CD) is considered the gold standard in the treatment of PD. However, long-term treatment with LD often leads to the development of motor complications. Motor complications include motor fluctuations and d...

Continuous Drug Delivery Aiming Continuous Dopaminergic Stimulation in Parkinson's Disease.

Continuous dopaminergic stimulation in Parkinson's disease (PD) has several advantages over pulsatile, non-continuous, stimulation. These therapies currently consist of pump-based and transcutaneous therapies and are based on a more constant delivery of the dopaminergic drug resulting in continuous dopaminergic stimulation and a more stable treatment effect. Several clinical and experimental observations have shown that continuous stimulation of dopaminergic receptors induces fewer complications, such as dy...

Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study.

Safinamide (Xadago) is a newly approved selective MAO-B inhibitor for the treatment of Parkinson's Disease (PD). The X-TRA study investigated the efficacy and tolerability of the substance under clinical practice conditions.

A punch in the gut - Intestinal inflammation links environmental factors to neurodegeneration in Parkinson's disease.

Parkinson's disease (PD) is an etiologically heterogeneous disorder. Experimental, clinical and epidemiological data suggest that intestinal inflammation contributes to the pathogenesis of PD. This article reviews recent literature on gut microbiota and intestinal inflammation in PD. We propose that intestinal inflammation links environmental factors (e.g. an altered gut microbiota composition) to neurodegeneration in (genetically susceptible) PD patients. In addition, there is an epidemiological and geneti...

When to Start Levodopa Therapy for Parkinson's Disease.

Contralateral levodopa-induced hemichorea in a patient with severe asymmetric Parkinson's disease.

The hidden side of Parkinson's disease: studying pain, anxiety and depression in animal models.

Parkinson's disease is a neurodegenerative disease leading to the loss of midbrain dopamine neurons. It is well known and characterized by motor symptoms that are secondary to the loss of dopamine innervation, but it is also accompanied by a range of various non-motor symptoms, including pain and psychiatric disorders such as anxiety and depression. These non-motor symptoms usually appear at early stages of the disease, sometimes even before the first motor symptoms, and have a dramatic impact on the qualit...

Effects of continuous subcutaneous apomorphine infusion in Parkinson's disease without cognitive impairment on motor, cognitive, psychiatric symptoms and quality of life.

Treatment optimization using continuous subcutaneous apomorphine infusion (CSAI) improves the control of motor fluctuations of patients with Parkinson's disease (PD). Although CSAI seems to be cognitively and behaviorally safe and to improve the quality of life, very few studies have investigated its influence in these domains, especially in patients without cognitive impairment.

Dietary modifications for weight loss and weight loss maintenance.

Worldwide obesity rates remain at a rise, and to treat obesity is at the top of the global public health agenda. In 2013, the AHA/ACC/TOS obesity management guidelines were published, in essence suggesting that any dietary scheme seems to be effective for weight loss, as long as it can induce a sustainable energy deficit. In the present review, we update and critically discuss available information regarding dietary modifications for weight loss and weight loss maintenance, published after the 2013 guidelin...

Quick Search